# Question Pool for Medical Quiz Escape Room - Hemophilia Escape Room
# Generated: 2025-01-12
# 
# UPUTE:
# 1. Svaka stanica ima isti pool od 21 pitanja
# 2. Pitanja se distribuiraju tako da svaka grupa dobije 3 različita pitanja
# 3. Na kraju svaka grupa vidi različita pitanja, ali ukupno se pokrije svih 21 pitanja

# Zajednički pool pitanja za sve stanice - Hemophilia
all_questions = [
    {
        "question": "Knowing the type of F8 mutation (null or non-null) in a patient with hemophilia A provides useful information for several aspects of disease management. What is its most important clinical use?",
        "options": [
            "A) Confirm the hemophilia A diagnosis",
            "B) Predict inhibitor formation risk",
            "C) Determine the severity of bleeding symptoms", 
            "D) Guide treatment strategy",
            "E) Guide decisions on immune tolerance induction (ITI) success"
        ],
        "correct": "B"
    },
    {
        "question": "Which Bethesda unit (BU) value is typically associated with high-titer inhibitors in hemophilia A?",
        "options": [
            "A) 0.5 BU",
            "B) 10 BU",
            "C) 5 BU",
            "D) 20 BU",
            "E) 30 BU"
        ],
        "correct": "C"
    },
    {
        "question": "Among PUPs with severe hemophilia A who develop inhibitors, what percentage are high-titer inhibitors?",
        "options": [
            "A) Approximately 10%",
            "B) Approximately 20%",
            "C) Approximately 30%",
            "D) Approximately 70%",
            "E) Approximately 50%"
        ],
        "correct": "D"
    },
    {
        "question": "In previously untreated patients with severe hemophilia A, how does on-demand treatment compare to prophylaxis in terms of inhibitor development risk?",
        "options": [
            "A) It increases the risk due to sudden high-dose exposures",
            "B) It has no impact — only genetics determine inhibitor risk",
            "C) It lowers the risk compared to prophylaxis",
            "D) Inhibitor development is entirely unpredictable",
            "E) It increases the risk only if plasma-derived products are used"
        ],
        "correct": "A"
    },
    {
        "question": "Which treatment is usually used to get rid of inhibitors in hereditary hemophilia A but NOT in acquired hemophilia A?",
        "options": [
            "A) Immunosuppressive therapy",
            "B) Bypassing agents",
            "C) Plasma exchange",
            "D) Factor VIII replacement therapy",
            "E) Immune Tolerance Induction (ITI)"
        ],
        "correct": "E"
    },
    {
        "question": "In hemophilia A patients undergoing immune tolerance induction (ITI) therapy, which factor most influences the success rate of ITI?",
        "options": [
            "A) Patient's blood type",
            "B) Baseline factor VIII activity level",
            "C) Peak inhibitor titer before starting ITI",
            "D) Age at diagnosis",
            "E) Type of factor VIII product used"
        ],
        "correct": "C"
    },
    {
        "question": "How does Hemlibra (emicizumab) work in hemophilia A patients?",
        "options": [
            "A) Replaces factor VIII directly",
            "B) Mimics the function of activated factor VIII by bridging activated factor IX and factor X",
            "C) Stimulates the production of endogenous factor VIII",
            "D) Inhibits fibrinolysis",
            "E) Activates thrombin through a pathway independent of FVIII cascade"
        ],
        "correct": "B"
    },
    {
        "question": "Which one of the following statements is true regarding standard coagulation assays in patients treated with Hemlibra (emicizumab)?",
        "options": [
            "A) Hemlibra does not affect any coagulation tests.",
            "B) Hemlibra affects only Factor VIII activity tests, not inhibitor tests.",
            "C) Hemlibra affects only inhibitor tests, not Factor VIII activity tests.",
            "D) Hemlibra affects both Factor VIII activity and inhibitor tests",
            "E) Hemlibra causes low Factor VIII activity results in all tests."
        ],
        "correct": "D"
    },
    {
        "question": "For breakthrough bleeding in Hemophilia A patients without inhibitors on Hemlibra, the recommended treatment is:",
        "options": [
            "A) Standard factor VIII concentrate",
            "B) Recombinant activated factor VII (rFVIIa) NovoSeven",
            "C) Activated prothrombin complex concentrate aPCC (FEIBA®)",
            "D) Aspirin",
            "E) Desmopressin (DDAVP)"
        ],
        "correct": "A"
    },
    {
        "question": "For breakthrough bleeding in Hemophilia A patients with inhibitors on Hemlibra, the recommended first-line treatment is:",
        "options": [
            "A) Standard factor VIII concentrate",
            "B) Activated prothrombin complex concentrate (aPCC – FEIBA®)",
            "C) Recombinant activated factor VII (rFVIIa – NovoSeven)",
            "D) Cryoprecipitate",
            "E) Fresh frozen plasma (FFP)"
        ],
        "correct": "C"
    },
    {
        "question": "Which of these characteristics is most important for making Nuwiq® suitable for personalized prophylaxis in hemophilia A?",
        "options": [
            "A) Good recovery after infusion",
            "B) Stable and predictable clearance",
            "C) Low variability between patients",
            "D) It contains von Willebrand factor",
            "E) It is administered subcutaneously"
        ],
        "correct": "B"
    },
    {
        "question": "In the NuProtect study, what was the cumulative incidence of high-titer inhibitors in previously untreated patients (PUPs) treated with Nuwiq®?",
        "options": [
            "A) 43.2%",
            "B) 30.7%",
            "C) 5%",
            "D) 60%",
            "E) 17.6%"
        ],
        "correct": "E"
    },
    {
        "question": "In the NuProtect study, what was the inhibitor development rate in PUPs with non-null mutations treated with Nuwiq®?",
        "options": [
            "A) No inhibitors were observed",
            "B) Higher than plasma-derived FVIII/VWF products in the SIPPET study",
            "C) Lower compared to plasma-derived FVIII/VWF products in the SIPPET study",
            "D) Higher than recombinant FVIII from hamster cell lines in the SIPPET study",
            "E) Higher than in patients with null mutations"
        ],
        "correct": "A"
    },
    {
        "question": "A patient with moderate Hemophilia B is scheduled for dental extraction. He has no history of inhibitors. Which of the following is the best prophylactic approach to minimize bleeding risk?",
        "options": [
            "A) No treatment needed since it is mild hemophilia and the procedure is minor",
            "B) Administer desmopressin before the procedure",
            "C) Use recombinant activated Factor VII (rFVIIa) prophylactically",
            "D) Administer Factor IX concentrate before and after the procedure",
            "E) Administer tranexamic acid alone without factor replacement"
        ],
        "correct": "D"
    },
    {
        "question": "Which of the following is the main limitation of standard recombinant factor IX concentrates compared to plasma-derived factor IX products in Hemophilia B treatment?",
        "options": [
            "A) High risk of inhibitor development",
            "B) Lower in vivo recovery requiring larger or more frequent dosing",
            "C) Poor viral inactivation in manufacturing",
            "D) Ineffectiveness in severe bleeding episodes",
            "E) Short shelf life"
        ],
        "correct": "B"
    },
    {
        "question": "Which of the following complications is more common in Hemophilia B compared to Hemophilia A?",
        "options": [
            "A) Development of inhibitors",
            "B) Allergic reactions including anaphylaxis during factor replacement",
            "C) Joint arthropathy",
            "D) Intracranial hemorrhage",
            "E) Thrombotic events during prophylaxis"
        ],
        "correct": "B"
    },
    {
        "question": "During pregnancy, levels of von Willebrand factor (VWF) and factor VIII:",
        "options": [
            "A) Decrease progressively",
            "B) Remain unchanged",
            "C) Increase significantly, especially in the third trimester",
            "D) Decrease only in the first trimester",
            "E) Fluctuate unpredictably"
        ],
        "correct": "C"
    },
    {
        "question": "What is a major risk concerning von Willebrand factor (VWF) levels after delivery?",
        "options": [
            "A) Rapid drop in VWF and factor VIII causing delayed postpartum hemorrhage",
            "B) Sustained elevated VWF leading to thrombosis",
            "C) No significant change postpartum",
            "D) Development of inhibitors",
            "E) Conversion into inactive form"
        ],
        "correct": "A"
    },
    {
        "question": "Why is preserving the multimer distribution of von Willebrand factor (VWF) in Wilate® important?",
        "options": [
            "A) Helps VWF maintain plasma half-life",
            "B) Abnormal distribution compromises FVIII stabilization",
            "C) Large multimers ensure platelet adhesion and effective clot formation in surgery, childbirth, trauma",
            "D) Influences inhibitor risk",
            "E) Prevents need for immunosuppression"
        ],
        "correct": "C"
    },
    {
        "question": "Qfitlia (fitusiran) is a new non-factor therapy used to treat hemophilia A or B. It works by silencing the production of antithrombin in the liver, which increases thrombin generation. What is a known disadvantage or risk associated with fitusiran therapy in patients with hemophilia?",
        "options": [
            "A) Liver toxicity",
            "B) Increased risk of thrombotic events due to excessive thrombin generation",
            "C) High risk of inhibitor formation",
            "D) Limited efficacy in factor V deficiency",
            "E) Ineffective in liver dysfunction"
        ],
        "correct": "B"
    },
    {
        "question": "Which of the following are potential concerns related to PEGylation of extended half-life (EHL) clotting factor products?",
        "options": [
            "A) Development of anti-PEG antibodies",
            "B) Risk of hypersensitivity/allergic reactions",
            "C) Interference with laboratory assays",
            "D) Risk of PEG accumulation in tissues",
            "E) All of the above"
        ],
        "correct": "E"
    }
]

# Pool pitanja za sve stanice - sve stanice imaju isti pool od 21 pitanja
station1_questions = all_questions
station2_questions = all_questions
station3_questions = all_questions
station4_questions = all_questions
station5_questions = all_questions
station6_questions = all_questions
station7_questions = all_questions